Adjuvant technology for long-lasting effective immune response

Dr. Chan Harjivan serves as Chief Operating Officer. Chan brings to SaponiQx extensive experience leading R&D strategy, spanning from discovery through to product launch. He is an expert at innovation management, public private partnerships, and global health. Chan’s previous positions include Senior Advisor for the U.S. Department of Health & Human Services (HHS) Operation Warp Speed, Partner and Managing Director for the Boston Consulting Group and 17 years as the Global Health lead at PwC. He holds a PharmD from the University of Maryland, and an MBA from the University of Oxford, and an MPH from Johns Hopkins University.

Dr. John Baldoni has developed an expansive portfolio over 40+ years in the pharmaceutical industry. His previous positions include Senior Vice President of Drug Discovery, and Senior Vice President of Platform Technology and Science (PTS) at GSK Pharma R&D. His experience spans chemical entity design, preclinical activity, biopharmaceutical development, commercialization, and discovery modernization. John has led several high-profile cross-functional problem-solving and strategic initiatives and is Co-Founder and Chair of the Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium’s Governing Board.